^
    Back
    Association details:
    Biomarker:EGFR wild-type
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cancer Med
    Title:

    Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer

    Published date:
    09/02/2022
    Excerpt:
    Treatment-naive Chinese patients with non-squamous stage IV EGFR/ALK mutation-negative NSCLC were randomized 1:1 to receive 4 or 6 cycles of APP or PP….Among Chinese patients in IMpower132, PFS benefit was seen with APP versus PP.
    Secondary therapy:
    cisplatin + pemetrexed; carboplatin + pemetrexed
    DOI:
    https://doi.org/10.1002/cam4.5144
    Trial ID:
    IMpower 132